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Abstract 
 
 
The histological therapeutic effect seen after surgery following 
NAC is said to relate to the prognosis of the patient .We need to 
consider not only invasive lesions remained, but also intra-ductal 
components or lymph node metastasis. We used the RCB index 
and compared it with the conventional method of judging the 
histopathological therapeutic effect. We also investigated the 
clinico-pathological features as well as recurrence and the 
prognosis by the RCB index. 
We studied 244 cases of primary breast cancer in 238 patients who 
had undergone surgery after NAC in Showa university hospital 
between 2005 and 2014. We classified the cases into groups based 
on the Japanese Breast Cancer Society’s criteria for evaluating the 
histological therapeutic effect and the RCB index. The cases were 
analyzed in regard to various clinico-pathological factors. The 
prognosis was evaluated by drawing recurrence-free survival 
curves using the Kaplan-Meier method, and the log rank test was 
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used to analyze for statistical significance. 
 
We evaluate the RCB index values for cases of Grade 0–1b that 
had a certain degree of residual tumor tissue. 
Comparison of the recurrence-free survival rates in each of the 
RCB index groups indicated a significant correlation. 
A significant correlation between the RCB index and the 
recurrence-free survival period, only for patients with some degree 
of residual malignancy even after chemotherapy. We think that the 
RCB index can be used for carrying out more precise prediction of 
recurrence. 
 
 
Key Words: 
 
Breast cancer, Neoadjuvant chemotherapy (NAC), 
 
RCB (residual cancer burden) index, pathology, surgery 
5  
 
 
1. Introduction 
 
 
Patients with invasive breast cancer that is operable show similar 
survival whether they undergo surgery following neoadjuvant 
chemotherapy (NAC) or have surgery first and then receive 
chemotherapy 1–3). Also, the histological therapeutic effect seen 
in surgical specimens following NAC is said to relate to the 
prognosis of the patient, and long-term survival is obtained 
especially in patients diagnosed as having achieved pathological 
complete response (pCR) 2)4). A meta-analysis of 12 recent clinical 
studies of NAC for breast cancer reported that pCR can serve as a 
surrogate endpoint for event-free survival (EFS) and/or overall 
survival (OS)5). In general, the most commonly used criteria for 
histological evaluation are the diagnostic criteria of Fisher et al. 
that were employed in the NSABP B-18 study4). It was assumed 
that no invasive lesions remained, and intra-ductal components or 
lymph node metastasis of cancers were not taken into account. 
Then, in the later NSABP B-27 study,  evaluation of    intraductal 
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components was performed in addition to the diagnostic criteria of 
Fisher et al. 6). Recently, it has been said that evaluation of the 
residual presence of lymph node metastases should also be 
performed 5). We therefore consider that the histological 
evaluation criteria must be decided upon. Needless to say, the 
objectivity and reproducibility of histological evaluations will be 
very important in such determinations. 
The residual cancer burden (RCB) index proposed by Symmans et 
al. 7) has been used in numerous large-scale clinical studies, 
including I-SPY (1,2), GEICAM, ACOSOG (Z11103), CALGB 
(40601, 40603), NSABP (B-40, B-41), and ABCSG (34), and its 
reproducibility has been evaluated 8). Based on this background, 
we used the RCB index and compared it with the conventional 
method of judging the histopathological therapeutic effect, that is, 
by evaluating the status of residual invasive lesions. We also 
investigated the clinico-pathological features as well as recurrence 
and the prognosis by the RCB index. 
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2. Materials and Methods 
 
 
1) Methods 
 
The subjects of this study were 244 cases of primary breast cancer 
in 238 patients who had undergone surgery after NAC in Showa 
university hospital between 2005 and 2014. All the subjects were 
women, and 6 patients had bilateral synchronous breast cancer. 
We collected the clinical and pathological information of the study 
subjects and created a database. We performed a retrospective 
survey of the medical records regarding postoperative recurrence 
and death. We classified the cases into 2 groups (Grade 0, 1a, 1b, 
2a and Grade 2b, 3) based on the Japanese Breast Cancer Society’s 
criteria for evaluating the histological therapeutic effect. And we 
also classified them into 2 groups (RCB -0, 1 and RCB-2, 3) after 
calculating the RCB index for each case. The cases were analyzed 
in regard to various clinico-pathological factors including age, 
clinical stage, histological type, vascular invasion, lymph node 
metastasis,     biomarkers,     chemotherapy     regimen,   surgical 
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procedure, recurrence, death, etc. We analyzed them by using t- 
test and chi-square test. And the prognosis was evaluated by 
drawing recurrence-free survival curves using the Kaplan-Meier 
method, and the log rank test was used to analyze for statistical 
significance. 
The biomarker findings were classified as follows: ≥10% ER•PgR 
was defined as positive, for HER2 only score 3 was considered 
positive, and ≥30% Ki67 was defined as positive. 
 
 
2) About the Japanese Breast Cancer Society’s criteria 
 
The Japanese Breast Cancer Society’s criteria classifies cases into 
groups of Grade 0 to Grade 3 based on evaluation the histological 
therapeutic effect (Table 6) 9). 
 
 
3) About RCB index 
 
The extent of residual disease (RD) in the post-treatment surgical 
resection specimen could be determined from bidimensional 
diameters of the primary tumor  bed in the  resection     specimen 
9  
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(d1and d2), the proportion of the primary tumor bed that contains 
invasive carcinoma (finv), the number of axillary lymph nodes 
containing metastatic carcinoma (LN), and the diameter of the 
largest metastasis in an axillary lymph node (dmet). If multiple 
tumors were present, the dimensions of the largest were recorded. 
Bidimensional measurements of the primary tumor bed 
(millimeters) were combined as follows: 
𝑑𝑑𝑝𝑝𝑟𝑟𝑖𝑖𝑚𝑚  = √𝑑𝑑1𝑑𝑑2  
The proportion of invasive carcinoma (finv) within the cross 
sectional area of the primary tumor bed was estimated from the 
overall percent area of carcinoma (%CA) and then corrected for the 
component of in situ carcinoma (%CIS): 
𝑓𝑓𝑖𝑖𝑛𝑛𝑣𝑣    = (1 − (%𝐶𝐶𝐼𝐼𝑆𝑆/100))×(%𝐶𝐶𝐴𝐴/100)  
From the above, they defined RCB index as follows: 
 RCB  = 1.4(𝑓𝑓𝑖𝑖𝑛𝑛𝑣𝑣 𝑑𝑑𝑝𝑝𝑟𝑟𝑖𝑖𝑚𝑚 ) + [4(1 − 0.75𝐿𝐿𝑁𝑁)𝑑𝑑  𝑚𝑚𝑒𝑒𝑡𝑡 ]0.17  
They identified two cutoff points to assign patients with RD (not 
RCB-0) after NAC into one of three classes: RCB-1 (minimal RD), 
RCB-2  (moderate  RD),  and  RCB-3  (extensive  RD).  Two cutoff 
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points were determined sequentially by maximizing the profile 
log-likelihood of a multivariate Cox model that included the 
clinical covariates and the dichotomized RCB index. The first 
cutoff point (RCB-3 and RCB-1/2) was selected as the 87th 
percentile (RCB, 3.28), and the second (RCB-1 and RCB-2) 
corresponds to the 40th percentile (RCB, 1.36) 7). 
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3. Results 
 
Data on patients background characteristics for the 244 cases are 
compiled in Table 1. The mean patient age was 51.6 years, and the 
mean duration of follow-up was 30.5 (6-120) months. Recurrence 
was seen in 38 cases, and 11 cases died. The mean time from 
surgery until recurrence was 28.2 months, and the mean time 
until death was 46.1 months. 
About the pretreatment stage of the cases, no striking differences 
were found in the distributions of the disease stage in each group 
when using the criteria for evaluating the histological therapeutic 
effect according to the General Rules for Clinical and Pathological 
Recording of Breast Cancer or when using the RCB index (Table 
2). 
Table 3 shows data for the clinico-pathological factors for each of 
the histological therapeutic effect evaluation criteria of the 
General Rules for Clinical and Pathological Recording of Breast 
Cancer. There was a tendency for the diameter of invasive tumor 
and the degree of vascular invasion and lymph node metastasis to 
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increase as the percentage of residual invasive lesions increased. 
Stratification of the biomarker findings indicated that, compared 
with the overall distributions, Grade 0, 1a, 1b, 2a showed a 
tendency for more ER(+), HER2(-), ki67<30% cases, while Grade 
2a, 3 showed a tendency for more ER(-), HER2(+) and ER(-), 
HER2(-), ki67≥30% cases. In addition, the rates of recurrence and 
death were low in Grade 2b, 3, specifically 7.7% and 0.0%, 
respectively, whereas their rates were 17.7% and 5.8% in Grade 0, 
1a, 1b, 2a. But there were not significant differences. 
Next, Table 4 shows the results of stratification of the clinico- 
pathological factors for each RCB index group. Stratification of the 
biomarker findings indicated that, compared with the overall 
distributions, RCB-0, 1 showed a tendency for more cases of ER(-), 
HER2(+), while RCB-2, 3 showed a tendency for more cases of 
ER(+), HER2(-), ki67<30%. In addition, about the rates of 
recurrence and death, there were not significant differences 
between 2 groups. 
We drew the recurrence-free survival plots (Figure 3). The left plot 
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shows the curves for the Grade 0, 1a, 1b, 2a and Grade 2a, 3 groups 
based on the histological therapeutic effect evaluation criteria of 
the Japanese Breast Cancer Society. The right plot shows the 
curves for the RCB-0, 1 and RCB-2, 3 groups based on the RCB 
index. The recurrence-free survival plots were compared, but the 
analyses did not find statistically significant differences (p=0.1236 
and p=0.0645). 
Table 5 presents the results of stratification of the clinic- 
pathological factors for each RCB index groups for cases of Grade 
0–1b that had a certain degree of residual tumor tissue, after 
excluding the cases of pCR and nearly pCR, which are considered 
to have a good prognosis. Stratification of the biomarker findings 
indicated that the percentage of ER(+), HER2(-), ki67<30% cases 
tended to increase as the RCB index increased, whereas, 
conversely, the percentage of ER(+), HER2(+), ki67<30% cases 
tended to decrease. About the rates of recurrence and death, there 
were not significant differences between 2 groups. 
We drew the recurrence-free survival plots for cases of Grade 0–1b 
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that had a certain degree of residual tumor tissue (Figure 4). This 
plot shows the curves for the RCB-1 and RCB-2, 3 groups based on 
the RCB index for cases of Grade 0–1b. Comparison of the 
recurrence-free survival rates in each of the RCB index groups 
indicated a significant correlation (p=0.0483*). 
From the results, for cases that had a certain degree of residual 
tumor tissue, RCB index can be used for carrying out prediction of 
the outcomes. In addition, it is considered that we can treat the 
cases of RCB-1 group almost equally to RCB-0 (pCR). 
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4. Discussion 
 
 
In this study, we used the RCB index as a means for evaluating 
the status of residual tumors and investigated the histological 
therapeutic effect based on the criteria of the General Rules for 
Clinical and Pathological Recording of Breast Cancer, the clinical 
histopathological data, recurrence and the prognosis. 
Reports to date have identified various prognostic factors in 
patients who have undergone surgery following NAC. Those 
factors include the clinical stage, histological type, tumor diameter, 
axillary lymph node metastasis, vascular invasion, a multifocal 
pattern of residual tumors, tumor necrosis, hormone receptors, 
positive rate of HER2, ki67 cells, menopausal status, race 
(African-American), etc. 10–15). About hormone receptors,  
positive rate of HER2, ki67 cells, we resulted in the same 
conclusion to the past reports. Concretely, the cases they had good 
effects of NAC showed a tendency for more cases in which estrogen 
receptor was negative, HER2 was positive, and Ki-67 was high. 
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Most of those reports have rated the tumor diameter and axillary 
lymph node metastasis as the most important prognostic factors 
10–13). A recent report stated that it is better to use T0 N0 or T0/is 
N0 as the definition of pCR 5). In our present paper, we used the 
RCB index, which not only takes into consideration of the primary 
lesion and axillary lymph node metastasis, but may also be a more 
accurate prognostic index since it is a numerical rating. 
Table 6 shows the other criteria used for evaluating the 
histological therapeutic effect16). 
The RCB index that we used has been employed in numerous 
clinical studies 8). In addition, the reproducibility of the RCB 
index has been evaluated as high, with an RCB category 
concordance rate of 0.989 8). As important items that should be 
included in pathology reports, one report stated pCR/non-pCR, the 
T stage, N stage, and RCB index if not available, 2 perpendicular 
diameters of the tumor 17). 
Our present results found a significant correlation between the 
RCB  index  and  the  recurrence-free  survival  period,  only    for 
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patients with some degree of residual malignancy even after 
chemotherapy. We think that the RCB index can be used for 
carrying out more precise prediction of recurrence. However, the 
RCB index did not show a significant correlation with survival. 
Noting that the mean 5-year survival was in excess of 90% for 
stage II breast cancer 18), for which chemotherapy is indicated, it 
is difficult to claim that a mean follow-up period of 30.5 months is 
even close to being sufficient. Thus, the issue of the duration of 
follow-up warrants further investigation. 
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Figure Legends and Tables 
Figure 1 : RCB index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RCB = 1.4(𝑓𝑓 𝑑𝑑 + [4(1 − 0.75𝐿𝐿𝑁𝑁)𝑑𝑑 ]0.17 
𝑖𝑖𝑛𝑛𝑣𝑣 𝑝𝑝𝑟𝑟𝑖𝑖𝑚𝑚) 
𝑑𝑑𝑝𝑝𝑟𝑟𝑖𝑖𝑚𝑚  = √𝑑𝑑1𝑑𝑑2 𝑚𝑚𝑒𝑒𝑡𝑡  
𝑓𝑓𝑖𝑖𝑛𝑛𝑣𝑣   = (1 − (%𝐶𝐶𝐼𝐼𝑆𝑆/100))×(%𝐶𝐶𝐴𝐴/100) 
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The pathological variables included bidimensional diameters of the primary tumor 
bed (d1, d2), the proportion of primary tumor area containing invasive carcinoma 
(finv), the number of positive lymph nodes (LN), and the diameter of the largest 
nodal metastasis (dmet). The diameter is considered that the tumor was exist before 
NAC (A). The proportion of invasive carcinoma (finv) within the cross sectional area 
of the primary tumor bed was estimated from the overall percent area of carcinoma 
(%CA) and then corrected for the component of in situ carcinoma (%CIS). 
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Figure 2 : The overall percent area of carcinoma (%CA) 
 
 
 
We evaluated the overall percent area of carcinoma (%CA) like these figures to 
calculate RCB index. 
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Table 1 : Patient background characteristics 
 
 
  n=244       
Age Mean (Range) 51.6  (26-74)  Chemotherapy FEC 9  
T stage T1 60 24.6%  FEC→PTX (+Her) 67 (+9)  
T2 124 50.8%  FEC→DTX (+Her) 88 (+31)  
T3 22 9.0%  FEC→TC +Her 1  
T4 36 14.8%  FEC→GEM+Carboplatin 4  
Uncertain 2 0.8%  Bev+PTX 3  
N stage N0 137 56.1%  Pertuzumab+DTX +Her 2  
N1 97 39.8%  Bev+PTX+Eribulin 1  
N2 3 1.2%  DTX+CPA +HER 1  
N3 5 2.0%  TC (+Her) 12 (+5)  
Uncertain 2 0.8%  PTX (+Her) 5 (+1)  
M stage M(+) 3 1.2%  DTX 3  
M(-) 239 98.0%  Uncertain 2  
Uncertain 2 0.8%  Operation Partial resection 111 45.5% 
Histlogic type IDC 227 93.0%  Total resection 133 54.5% 
Special type 17 7.0%  Recurrence None 206 84.2% 
Biomarker ER(+) 138 56.6%  Local recurrence 2 1.0% 
ER(-) 97 39.8%  Distant recurrence 36 14.8% 
Uncertain 9 3.6%  Death None 233 95.3% 
PgR(+) 106 43.4%  Death with recurrence 10 4.3% 
PgR(-) 127 52.0%  Death of other disease 1 0.4% 
Uncertain 11 4.6%   (Lung metastasis of overian  cancer)  
HER2(+) 58 23.8%      
HER2(-) 177 72.5%      
Uncertain 9 3.7%      
Ki67(+) 106 43.4%      
Ki67(-) 93 38.1%      
Uncertain 45 18.5%      
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Table 2 : The pretreatment stage of the cases 
 
 
 T N M 
T1 T2 T3 T4 Uncertain N0 N1 N2 N3 Uncertain M(+) M(-) Uncertain 
Grade 0,1 38 
24.8% 
76 
49.7% 
13 
8.5% 
25 
16.3% 
1 
0.7% 
83 
54.2% 
65 
42.5% 
2 
1.3% 
2 
1.3% 
1 
0.7% 
2 
1.3% 
150 
98.0% 
1 
0.7% 153 
Grade 2 11 
23.4% 
25 
53.1% 
5 
10.6% 
6 
12.8% 
0 
0.0% 
31 
66.0% 
16 
34.0% 
0 
0.0% 
0 
0.0% 
0 
0.0% 
0 
0.0% 
47 
100.0% 
0 
0.0% 47 
Grade 3 11 
25.0% 
23 
52.3% 
4 
9.1% 
5 
11.4% 
1 
2.3% 
23 
52.3% 
16 
36.4% 
1 
2.3% 
3 
6.8% 
1 
2.3% 
1 
2.3% 
42 
95.4% 
1 
2.3% 44 
RCB-0 9 
23.7% 
20 
52.6% 
4 
10.5% 
4 
10.5% 
1 
2.6% 
22 
57.9% 
13 
34.2% 
1 
2.6% 
1 
2.6% 
1 
2.6% 
0 
0.0% 
37 
97.4% 
1 
2.6% 38 
RCB-1 14 
27.5% 
25 
49.0% 
6 
11.8% 
5 
9.8% 
1 
2.0% 
36 
70.6% 
13 
25.5% 
0 
0.0% 
1 
2.0% 
1 
2.0% 
1 
2.0% 
49 
96.0% 
1 
2.0% 51 
RCB-2 29 
25.2% 
60 
52.2% 
9 
7.8% 
17 
14.8% 
0 
0.0% 
69 
60.0% 
44 
38.3% 
1 
0.9% 
1 
0.9% 
0 
0.0% 
1 
0.9% 
114 
99.1% 
0 
0.0% 115 
RCB-3 8 
20.0% 
19 
47.5% 
3 
8.7% 
10 
25.0% 
0 
0.0% 
10 
25.0% 
27 
67.5% 
1 
2.5% 
2 
5.0% 
0 
0.0% 
1 
2.5% 
39 
97.5% 
0 
0.0% 40 
All cases 60 
24.6% 
124 
50.8% 
22 
9.0% 
36 
14.8% 
2 
0.8% 
137 
56.1% 
97 
39.8% 
3 
1.2% 
5 
2.0% 
2 
0.8% 
3 
1.2% 
239 
98.0% 
2 
0.8% 244 
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Table 3 : The clinico-pathological data of Grade 0, 1a, 1b, 2a and Grade 2b,3 group 
 
 
 
 
All cases Grade 0, 1, 2a Grade 2b, 3 p value 
244 192 (78.7%) 52 (21.3%) <0.05 
Age Mean （Range） 51.6  (26-74) 52.1 (26-74) 51 (34-71) 0.2176 
Tumor diameter (mm) Mean （Range） (mm) 17.9  (0-105) 22.1 (0-105) 0.09 (0-3) <0.0001* 
Vessel invasion ly (+)  29 11.9% 29 15.1% 0 0.0% 0.0023* 
v (+)  3 1.2% 3 1.6% 0 0.0% 0.3644 
Lymph node metastasis N (+)  82 33.6% 78 40.6% 0 0.0% <0.0001* 
Biomarker ER+, HER2- ki67≧30% 31 12.7% 26 13.5% 5 9.6% 0.4508 
 ki67<30% 68 27.9% 66 34.4% 2 3.8% <0.0001* 
 Uncertain 16 6.6% 16 8.3% 0 0.0%  
ER+, HER2+ ki67≧30% 11 4.5% 8 4.2% 3 5.8% 0.6213 
 ki67<30% 9 3.7% 6 3.1% 3 5.8% 0.3695 
 Uncertain 3 1.2% 3 1.6% 0 0.0%  
ER-, HER2+ ki67≧30% 21 8.6% 10 5.2% 11 21.2% 0.0003* 
 ki67<30% 6 2.5% 2 1.0% 4 7.7% 0.0060* 
 Uncertain 8 3.3% 6 3.1% 2 3.8%  
ER-, HER2- ki67≧30% 43 17.6% 28 14.6% 15 28.8% 0.0166* 
 ki67<30% 10 4.1% 10 5.2% 0 0.0% 0.0929 
 Uncertain 9 3.7% 5 2.6% 4 7.7%  
Uncertain  9 3.7% 6 3.1% 3 5.8%  
Recurrence －  206 84.4% 158 82.3% 48 92.3%  
＋  38 15.6% 34 17.7% 4 7.7% 0.0772 
Death －  233 95.5% 181 94.2% 52  100.0%  
＋  11 4.5% 11 5.8% 0 0.0% 0.0773 
Observation period Mean(Range) (Months) 30.5  (6-120) 31.6 (6-120) 28.1 (6-93) 0.4842 
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Table 4 : The clinico-pathological data of RCB-0, 1 and RCB-2, 3 group 
 
 
 
 
All cases RCB-0, 1 RCB-2, 3 p value 
244 89, 36.5% 155, 63.5% <0.05 
Age Mean （Range） 51.6  (26-74) 51.8 (31-74) 51.5 (26-74) 0.9809 
Tumor diameter (mm) Mean （Range） (mm) 17.9  (0-105) 4.47 (0-35) 27.1 (0-105) <0.0001* 
Vessel invasion ly (+)  29 11.9% 2 2.2% 27 17.4% 0.0013* 
v (+)  3 1.2% 0 0.0% 3 1.9% 0.1866 
Lymph node metastasis N (+)  82 33.6% 2 2.2% 80 51.6% <0.0001* 
Biomarker ER+, HER2- ki67≧30% 31 12.7% 11 12.4% 20 12.9% 0.6016 
 ki67<30% 68 27.9% 7 7.9% 61 39.4% <0.0001* 
 Uncertain 16 6.6% 3 3.4% 13 8.4%  
ER+, HER2+ ki67≧30% 11 4.5% 4 4.5% 7 4.5% 0.9937 
 ki67<30% 9 3.7% 6 6.7% 3 1.9% 0.0552 
 Uncertain 3 1.2% 0 0.0% 3 1.9%  
ER-, HER2+ ki67≧30% 21 8.6% 14 15.7% 7 4.5% 0.0026* 
 ki67<30% 6 2.5% 5 5.6% 1 0.6% 0.0158* 
 Uncertain 8 3.3% 7 7.9% 1 0.6%  
ER-, HER2- ki67≧30% 43 17.6% 20 22.5% 23 14.8% 0.132 
 ki67<30% 10 4.1% 2 2.2% 8 5.2% 0.2691 
 Uncertain 9 3.7% 5 5.6% 4 2.6%  
Uncertain  9 3.7% 5 5.6% 4 2.6%  
Recurrence －  206 84.4% 78 87.6% 128 82.6%  
＋  38 15.6% 11 12.4% 27 17.4% 0.2941 
Death －  233 95.5% 86 93.3% 147 94.2%  
＋  11 4.5% 3 6.7% 8 5.8% 0.5164 
Observation period Mean(Range) (Months) 30.5  (6-120) 31.3(6-120) 29.9(8-110) 0.3378 
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Figure 3 : The recurrence-free survival (RFS) plots 
 
 
 
This figures show the recurrence-free survival (RFS) plots. The left plot shows the 
curves for the Grade 0, 1a, 1b, 2a and Grade 2b, 3 groups based on the histological 
therapeutic effect evaluation criteria of the Japanese Breast Cancer Society, while 
the right plot shows the curves for the RCB-0, 1 and RCB-2, 3 groups based on the 
RCB index. The recurrence-free survival plots were compared, but the analyses did 
not find statistically significant differences (P=0.1236 and P=0.0645). 
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Table 5 : The clinico-pathological data of RCB-0, 1 and RCB-2, 3 group for cases of 
Grade 0–1b 
 
 
 
Grade 0-1b RCB-1 RCB-2, 3 p value 
153 17, 11.1% 136, 88.9% <0.05 
Age Mean （Range） 52.3 (31-74) 57.2 (38-74) 51.7 (31-74) 0.1037 
Tumor diameter (mm) Mean （Range） (mm) 27.2 (1-105) 11.8 (1-35) 29.2 (4-105) <0.0001* 
Vessel invasion ly (+)  24 15.7% 2 11.8% 22 16.2% 0.6928 
v (+)  3 2.0% 0 0.0% 3 2.2% 0.5641 
Lymph node metastasis N (+)  69 45.1% 0 0.0% 69 50.7% 0.0002* 
Biomarker ER+, HER2- ki67≧30% 19 12.4% 3 17.6% 16 11.8% 0.9099 
 ki67<30% 59 36.8% 2 11.8% 57 41.9% 0.0075* 
 Uncertain 14 5.7% 2 11.8% 12 8.8%  
ER+, HER2+ ki67≧30% 5 3.3% 0 0.0% 5 3.7% 0.4535 
 ki67<30% 5 3.3% 2 11.8% 3 2.2% 0.021* 
 Uncertain 1 0.7% 0 0.0% 1 0.7%  
ER-, HER2+ ki67≧30% 6 3.9% 0 0.0% 6 4.4% 0.41 
 ki67<30% 1 0.7% 0 0.0% 1 0.7% 0.7408 
 Uncertain 2 1.3% 1 5.9% 1 0.7%  
ER-, HER2- ki67≧30% 22 14.4% 1 5.9% 21 15.4% 0.3701 
 ki67<30% 8 5.2% 1 5.9% 7 5.1% 0.7922 
 Uncertain 5 3.3% 3 17.6% 2 1.5%  
Uncertain  6 3.9% 2 11.8% 4 2.9%  
Recurrence －  129 84.3% 16 94.1% 113 83.1%  
＋  24 15.7% 1 5.9% 23 16.9% 0.3118 
Death －  147 96.1% 17   100.0% 130 95.6%  
＋  6 3.9% 0 0.0% 6 4.4% 0.41 
Observation period Mean  (Range) (Months) 30.4 (6-120) 37.2 (9-120) 30 (6-110) 0.0755 
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Figure 4 : The recurrence-free survival (RFS) plots for cases of Grade 0–1b 
 
 
 
 
This figure shows the recurrence-free survival (RFS) plots. This plot shows the 
curves for the RCB-1 and RCB-2, 3 groups based on the RCB index for cases of Grade 
0–1b.Comparison of the recurrence-free survival rates in each of the RCB index 
groups indicated a significant correlation (p=0.0483*). 
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Table 6 : The other criteria used for evaluating the histological therapeutic effect 
 
 
 Year Criteria  for evaluating  the histological  therapeutic effect 
The Japanese Breast 
Cancer Society’s 
criteria 
2012 Grade 0 (No  Response)  Presence of little change in cancer   cells 
Grade 1 (Partially  Effective) 
1a (Mild Effect) Pleasence of changes in cancer cells inspite of the area, or severe 
changes in less than 1/3 cancer   cells 
1b (Moderate Effect) Presence of severe changes in more than 1/3 and less than 2/3 cancer 
cells 
Grade 2 (Quite  Effective) 
2a (High Effect) Presence of severe changes in more than 2/3 cancer cells, but presence 
of cancer nest  clearly 
2b (Extremely High  Effect) 
Presence of effect nearly Complete Response (Grade 3), but presence   of 
extremely a little cancer  cells 
Grade 3 
(Complete  Response)  Presence of necrosis, disappearance or replacement of glomerous or fibrous  tissue in all cancer cells 
NSABP B-18 criteria 1997 pCR No recognizable invasive tumor cells  present 
pPR The presence of scattered individual or small clusters of tumor in a desmoplastic or hyaline stroma 
pNR Tumors  not exhibiting  the changes  listed above 
Chevallier's grading 
system 
1993 Class  1 (pCR) Disappearance of all  tumor 
Class  2 (pCR) Presence of DCIS in the breast, no invasive carcinoma    and negative lymph node 
Class  3 (pPR) Presence of invasive carcinoma with stromal   alteration 
Class  4 (pNR) Few modifications of the tumoral   appearance 
Miller-Payne's grading 
system 
2003 Grade 1 (pNR) No change or some alteration to individual  malignant cells, but no reduction in overall    cellularity 
Grade 2 (pPR) A minor loss of tumor cells, but overall cellularity still high ; up to 30 % loss 
Grade 3 (pPR) Between an estimated 30% and 90% reduction in tumor   cells 
Grade 4 (almost  pCR) 
A marked disappearance of tumor cells such that only small clusters or widely dispersed indivisual  
cell remains ; >90% loss of tumor   cells 
grade 5 (pCR) 
No malignant cells identifiable in sections from the site of the tumor ; only vascular fibroelastotic 
dstroma remains, often containing macrophages ; however, ductal carcinoma in situ may be present 
Sataloff's grading 
system 
1995 Tumor T-A Total or near total therapeutic effect  (pCR) 
T-B >50% therapeutic effect, but less than total or near total   (pPR) 
T-C <50% therapeutic effect, but effect evident  (pPR) 
T-D No therapeutic effect  (pNR) 
Node N-A Evidence of therapeutic effect, no metastatic   disease 
N-B No nodal metastasis or therapeutic  effect 
N-C Evidence of therapeutic effect, but nodal metastatasis   present 
N-D Viable metastatic disease, no therapeutic  effect 
 
